117 related articles for article (PubMed ID: 1900466)
1. [Clinical significance of the fibrinolysis system].
Himmelreich G; Riess H
Dtsch Med Wochenschr; 1991 Mar; 116(11):426-30. PubMed ID: 1900466
[No Abstract] [Full Text] [Related]
2. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
Onundarson PT; Francis CW; Marder VJ
J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
[TBL] [Abstract][Full Text] [Related]
3. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
4. Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review.
Sane DC; Pizzo SV; Greenberg CS
Am J Hematol; 1989 May; 31(1):53-7. PubMed ID: 2495717
[TBL] [Abstract][Full Text] [Related]
5. Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI).
Gram J; Kluft C; Jespersen J
Thromb Haemost; 1987 Oct; 58(3):817-21. PubMed ID: 2448888
[TBL] [Abstract][Full Text] [Related]
6. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
[TBL] [Abstract][Full Text] [Related]
7. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D
Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655
[TBL] [Abstract][Full Text] [Related]
10. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.
Gram J
Dan Med Bull; 1990 Jun; 37(3):210-34. PubMed ID: 2192835
[TBL] [Abstract][Full Text] [Related]
11. [Variations in hemostasis and fibrinolysis during the treatment of acute myocardial infarct (AMI) with tissue-type plasminogen activator (TTPA). A study of 17 cases].
Izaguirre Avila R; Ruiz de Chávez Cervantes A; Villavicencio R; Gómez Trigos A; Mar Chavira R; Spíndola Mdel C; Casanova JM
Arch Inst Cardiol Mex; 1993; 63(3):235-40. PubMed ID: 8347053
[TBL] [Abstract][Full Text] [Related]
12. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
[TBL] [Abstract][Full Text] [Related]
13. Effect of caffein ingestion on plasma fibrinolytic potential.
Wojta J; Kirchheimer JC; Peska MG; Binder BR
Thromb Haemost; 1988 Apr; 59(2):337-8. PubMed ID: 3133816
[No Abstract] [Full Text] [Related]
14. [Intra-coronary thrombolysis for acute myocardial infarction].
Kimata S
Rinsho Byori; 1990 Jul; Suppl 86():11-24. PubMed ID: 2122047
[No Abstract] [Full Text] [Related]
15. Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Levi M; Lensing AW; Büller HR; Prandoni P; Dooijewaard G; Cuppini S; ten Cate JW
Thromb Haemost; 1991 Oct; 66(4):426-9. PubMed ID: 1796391
[TBL] [Abstract][Full Text] [Related]
16. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
17. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
Bachmann F
Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Collen D; Lijnen HR
Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
[TBL] [Abstract][Full Text] [Related]
19. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
Czyrski J
Wiad Lek; 1989 Apr; 42(7):450-2. PubMed ID: 2516932
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
